Molnupiravir and risk of post-acute sequelae of covid-19: cohort study

OBJECTIVE: To examine whether treatment with the antiviral agent molnupiravir during the first five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse health outcomes. DESIGN: Cohort study. SETTING: US Department of Veterans Affairs. PARTICIPANTS: 229 286 participants...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yan, Choi, Taeyoung, Al-Aly, Ziyad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126525/
https://www.ncbi.nlm.nih.gov/pubmed/37161995
http://dx.doi.org/10.1136/bmj-2022-074572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126525/
https://www.ncbi.nlm.nih.gov/pubmed/37161995
http://dx.doi.org/10.1136/bmj-2022-074572

Ejemplares similares